Table 2.
Predicted incremental cost-effectiveness ratios aggregated to super-region level compared to range of input data by super-region from Tufts registries.
| Super Region | Predicted ICER adjusted for cost-saving probabilities in 2017 US$ per DALY Averted (95% UI) |
Tufts registry dataset and additional extractions |
|||
|---|---|---|---|---|---|
| Minimum ICER in Tufts data and sensitivity analyses extractions in 2017 US$ per unit change in DALY or QALY | Minimum ICER location in Tufts data | Maximum ICER in Tufts data and sensitivity analyses extractions in 2017 US$ per unit change in DALY or QALY | Maximum ICER location in Tufts data | ||
| High-Income | 40,915 (6,382 to 153,130) |
95 | Argentina | 319,574 | Spain |
| North Africa and Middle East | 2,407 (374 to 8,884) |
3 | Iran | 10,224 | Iran |
| Central Europe, Eastern Europe, and Central Asia | 3,993 (618 to 14,726) |
1 | Uzbekistan | 12,964 | Albania |
| Southeast Asia, East Asia, and Oceania | 2,408 (375 to 8,845) |
1 | Cambodia | 418,802 | Mauritius |
| Latin America and Caribbean | 2,454 (380 to 9,085) |
2 | Haiti | 17,604 | Cuba |
| South Asia | 294 (45 to 1,065) |
15 | Pakistan | 1,543 | Bangladesh |
| Sub-Saharan Africa | 251 (38 to 903) |
0 | Angola | 1,373 | Cape Verde |
Population-weighted super-region predictions assuming 90% vaccine coverage, lifetime time horizon, healthcare payer perspective, 3% vaccine cost and burden discount rates, monovalent vaccine type, DALYs averted as health outcome measure, and no intervention as the comparator. ICER = incremental cost-effectiveness ratio, UI = uncertainty interval, QALY = quality-adjusted life-year, DALY = disability adjusted life-year.